Ask us your questions about our products, patient materials or organising a meeting.
InRange Clinical Summary
InRange - the first randomised, Phase 4 study to use Time-In-Range (TIR) as the primary endpoint to compare second generation basal insulin analogues Toujeo® and insulin degludec 100U/mL in people with T1DM.
Download this six page clinical summary about the InRange study and learn more about the study design, the key findings and more
Professor Richard Bergenstal presents the results of the InRange study. This study is the first randomised controlled trial to compare second generation basal insulin analogues Toujeo® and insulin degludec 100 U/mL. It compares adults with T1DM, using Time-in-Range (TIR) as the primary endpoint. Watch and learn about the study design and key findings.
Time in Range Guide
View the guide below to find out more about the impact of time in range on your patients.
MAT-XU-2205633 (v4.0) Date of Preparation: October 2023